| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
|
J Natl Cancer Inst
|
2002
|
12.07
|
|
2
|
Metastases in carcinoma; analysis of 1000 autopsied cases.
|
Cancer
|
1950
|
11.28
|
|
3
|
Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.
|
N Engl J Med
|
2003
|
7.64
|
|
4
|
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
|
N Engl J Med
|
1996
|
5.87
|
|
5
|
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
|
Cancer J
|
2001
|
3.56
|
|
6
|
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
|
N Engl J Med
|
1996
|
3.41
|
|
7
|
Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction.
|
Radiology
|
1993
|
3.18
|
|
8
|
Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.
|
N Engl J Med
|
1980
|
3.15
|
|
9
|
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
|
J Clin Oncol
|
2003
|
3.10
|
|
10
|
Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases.
|
Radiother Oncol
|
1986
|
3.07
|
|
11
|
The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study.
|
Radiother Oncol
|
1999
|
3.01
|
|
12
|
Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia.
|
Lancet
|
1989
|
3.00
|
|
13
|
Evidence for the secretion of an osteoclast stimulating factor in myeloma.
|
N Engl J Med
|
1974
|
2.97
|
|
14
|
SUV: standard uptake or silly useless value?
|
J Nucl Med
|
1995
|
2.96
|
|
15
|
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
|
Cancer
|
2004
|
2.80
|
|
16
|
Bisphosphonates: from the laboratory to the clinic and back again.
|
Bone
|
1999
|
2.55
|
|
17
|
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
|
Cancer
|
2003
|
2.52
|
|
18
|
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.
|
J Clin Oncol
|
1993
|
2.50
|
|
19
|
The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms.
|
N Engl J Med
|
1984
|
2.33
|
|
20
|
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
|
Cancer Res
|
2000
|
2.32
|
|
21
|
Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
|
Bone Miner
|
1986
|
2.23
|
|
22
|
The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group.
|
Cancer
|
1982
|
2.20
|
|
23
|
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
|
Br J Cancer
|
2001
|
2.14
|
|
24
|
Bisphosphonates induce apoptosis in human breast cancer cell lines.
|
Br J Cancer
|
2000
|
2.12
|
|
25
|
Bisphosphonates: clinical experience.
|
Oncologist
|
2004
|
2.12
|
|
26
|
Breast cancer cells interact with osteoblasts to support osteoclast formation.
|
Endocrinology
|
1999
|
2.11
|
|
27
|
Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound.
|
J Bone Miner Res
|
1994
|
1.84
|
|
28
|
Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells.
|
N Engl J Med
|
1987
|
1.82
|
|
29
|
Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.
|
Lancet
|
1992
|
1.80
|
|
30
|
Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.
|
J Clin Invest
|
1989
|
1.79
|
|
31
|
Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma.
|
Cancer
|
1985
|
1.74
|
|
32
|
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
|
Cancer
|
2004
|
1.68
|
|
33
|
Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.60
|
|
34
|
Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography.
|
J Clin Oncol
|
1999
|
1.58
|
|
35
|
Markers of bone turnover for the management of patients with bone metastases from prostate cancer.
|
Br J Cancer
|
2000
|
1.56
|
|
36
|
Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer.
|
Br Med J (Clin Res Ed)
|
1987
|
1.52
|
|
37
|
Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT.
|
J Nucl Med
|
2004
|
1.51
|
|
38
|
The role of bisphosphonates in the management of bone metastases in prostate cancer.
|
Can J Urol
|
2004
|
1.49
|
|
39
|
Molecular mechanisms of osteolytic bone metastases.
|
Cancer
|
2000
|
1.47
|
|
40
|
Pamidronate to reduce bone pain in normocalcaemic patient with disseminated prostatic carcinoma.
|
Lancet
|
1989
|
1.44
|
|
41
|
Tumor products and the hypercalcemia of malignancy.
|
J Clin Invest
|
1985
|
1.37
|
|
42
|
Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption.
|
Eur J Surg Oncol
|
1987
|
1.34
|
|
43
|
Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).
|
Br Med J (Clin Res Ed)
|
1987
|
1.33
|
|
44
|
Molecular mechanisms of action of bisphosphonates.
|
Bone
|
1999
|
1.33
|
|
45
|
Bisphosphonate treatment inhibits the growth of prostate cancer cells.
|
Cancer Res
|
2001
|
1.32
|
|
46
|
Palliative pamidronate treatment in patients with bone metastases from breast cancer.
|
J Clin Oncol
|
1993
|
1.32
|
|
47
|
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
|
J Clin Oncol
|
1996
|
1.31
|
|
48
|
Structure-activity relationships of various bisphosphonates.
|
Calcif Tissue Int
|
1983
|
1.31
|
|
49
|
Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group.
|
Bone Miner
|
1987
|
1.31
|
|
50
|
Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer.
|
Bone
|
1994
|
1.31
|
|
51
|
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
|
Leukemia
|
1998
|
1.27
|
|
52
|
Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
|
Am J Med
|
1993
|
1.23
|
|
53
|
Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma.
|
BMJ
|
1988
|
1.23
|
|
54
|
Morphometric evidence for bone resorption and replacement in prostate cancer.
|
Br J Urol
|
1991
|
1.22
|
|
55
|
Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.
|
Lancet
|
1983
|
1.20
|
|
56
|
Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists.
|
Radiother Oncol
|
2000
|
1.19
|
|
57
|
Metabolic effects of pamidronate in patients with metastatic bone disease.
|
Br J Cancer
|
1996
|
1.19
|
|
58
|
Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
|
Br J Cancer
|
1988
|
1.18
|
|
59
|
A systematic overview of radiation therapy effects in skeletal metastases.
|
Acta Oncol
|
2003
|
1.18
|
|
60
|
Quantitative histology of myeloma-induced bone changes.
|
Br J Haematol
|
1982
|
1.15
|
|
61
|
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
|
Cancer Invest
|
2002
|
1.13
|
|
62
|
[Remineralization and pain relief in bone metastases after after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study].
|
Strahlenther Onkol
|
1999
|
1.13
|
|
63
|
Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
|
Eur J Nucl Med Mol Imaging
|
2003
|
1.12
|
|
64
|
Comparative study of available medical therapy for hypercalcemia of malignancy.
|
Am J Med
|
1983
|
1.12
|
|
65
|
Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.
|
Calcif Tissue Int
|
1986
|
1.08
|
|
66
|
A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain.
|
Radiother Oncol
|
1992
|
1.08
|
|
67
|
Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
|
J Clin Oncol
|
1988
|
1.07
|
|
68
|
3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
|
Br J Cancer
|
1987
|
1.06
|
|
69
|
MMP inhibition and downregulation by bisphosphonates.
|
Ann N Y Acad Sci
|
1999
|
1.05
|
|
70
|
The role of bisphosphonates in breast and prostate cancers.
|
Endocr Relat Cancer
|
2004
|
1.05
|
|
71
|
Bone metastases: improving the therapeutic index.
|
Semin Oncol
|
1994
|
1.04
|
|
72
|
Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone.
|
Int J Cancer
|
1999
|
1.02
|
|
73
|
Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines.
|
Leukemia
|
2000
|
1.02
|
|
74
|
Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton.
|
J Urol
|
1985
|
1.02
|
|
75
|
18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy.
|
Ann Nucl Med
|
2004
|
1.01
|
|
76
|
Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line.
|
Br J Cancer
|
2001
|
1.00
|
|
77
|
Pain control by ionizing radiation of bone metastasis.
|
Int J Dev Biol
|
2004
|
0.99
|
|
78
|
Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis.
|
Cancer
|
1985
|
0.98
|
|
79
|
Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.
|
J Clin Invest
|
1982
|
0.98
|
|
80
|
Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease.
|
Br J Cancer
|
1992
|
0.96
|
|
81
|
Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat.
|
Cancer Res
|
1984
|
0.95
|
|
82
|
Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity.
|
Lancet
|
2000
|
0.95
|
|
83
|
The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials.
|
Pain
|
1998
|
0.94
|
|
84
|
Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.
|
Calcif Tissue Int
|
1991
|
0.93
|
|
85
|
90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.
|
Eur J Nucl Med Mol Imaging
|
2005
|
0.92
|
|
86
|
The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro.
|
Anticancer Drugs
|
2001
|
0.92
|
|
87
|
Diagnosis of occult bone metastases: positron emission tomography.
|
Clin Orthop Relat Res
|
2003
|
0.92
|
|
88
|
Irradiation of bone metastases in breast cancer patients: a randomized study with 1 year follow-up.
|
Radiother Oncol
|
1995
|
0.92
|
|
89
|
Production of interleukin-1 by bone marrow myeloma cells.
|
Blood
|
1989
|
0.92
|
|
90
|
The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro.
|
Br J Cancer
|
2002
|
0.92
|
|
91
|
Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessments of gray-level histogram in plain radiographs.
|
Int J Radiat Oncol Biol Phys
|
2003
|
0.91
|
|
92
|
Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
|
J Clin Oncol
|
1992
|
0.90
|
|
93
|
Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer.
|
Br J Urol
|
1992
|
0.89
|
|
94
|
Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
|
J Clin Oncol
|
1986
|
0.88
|
|
95
|
Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
|
Int J Cancer
|
2003
|
0.88
|
|
96
|
Renal failure associated with intravenous diphosphonates.
|
Lancet
|
1983
|
0.88
|
|
97
|
Treatment of bone metastases from breast cancer and myeloma with pamidronate.
|
Eur J Cancer
|
1991
|
0.87
|
|
98
|
Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer.
|
J Urol
|
1996
|
0.85
|
|
99
|
A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
|
Cancer
|
2001
|
0.84
|
|
100
|
Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys.
|
J Bone Miner Res
|
1998
|
0.83
|